{"component": "definition", "props": {"groups": [{"size": 52, "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "the-requirements", "type": "clause", "offset": [63, 79]}, {"key": "as-amended", "type": "definition", "offset": [113, 123]}, {"key": "from-time-to-time", "type": "clause", "offset": [124, 141]}, {"key": "foreign-equivalent", "type": "definition", "offset": [151, 169]}], "samples": [{"hash": "emr8ABMPfIp", "uri": "/contracts/emr8ABMPfIp#phase-i-study", "label": "Licensing Agreement", "score": 35.3063354492, "published": true}, {"hash": "8RyEuUuP1Vo", "uri": "/contracts/8RyEuUuP1Vo#phase-i-study", "label": "Collaboration and License Agreement (Monte Rosa Therapeutics, Inc.)", "score": 34.8535232544, "published": true}, {"hash": "7uWGVx1DHQa", "uri": "/contracts/7uWGVx1DHQa#phase-i-study", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 33.7994537354, "published": true}], "snippet": "means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. \u00a7 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "hash": "38a73ed8e29608639fb1604649722eca", "id": 1}, {"size": 49, "snippet_links": [{"key": "information-on", "type": "clause", "offset": [146, 160]}, {"key": "product-safety", "type": "clause", "offset": [161, 175]}, {"key": "the-non", "type": "clause", "offset": [288, 295]}, {"key": "united-states", "type": "clause", "offset": [296, 309]}], "samples": [{"hash": "gwXMfduYEwH", "uri": "/contracts/gwXMfduYEwH#phase-i-study", "label": "License, Development and Commercialization Agreement (Incyte Corp)", "score": 30.8261470795, "published": true}, {"hash": "72seS1H82Gs", "uri": "/contracts/72seS1H82Gs#phase-i-study", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 30.8261470795, "published": true}, {"hash": "eFoF27uKep1", "uri": "/contracts/eFoF27uKep1#phase-i-study", "label": "Collaboration and License Agreement (Incyte Corp)", "score": 28.4934978485, "published": true}], "snippet": "means a study in humans which provides for the first introduction into humans of a product, conducted in healthy volunteers or patients to obtain information on product safety, tolerability, pharmacological activity or pharmacokinetics, as more fully defined in 21 C.F.R. \u00a7 312.21(a) (or the non-United States equivalent thereof).", "hash": "d476b3a97938528167a222c50007d47b", "id": 2}, {"size": 26, "snippet_links": [{"key": "clinical-study", "type": "definition", "offset": [8, 22]}, {"key": "covered-product", "type": "definition", "offset": [30, 45]}, {"key": "purpose-of", "type": "clause", "offset": [82, 92]}, {"key": "determination-of", "type": "clause", "offset": [114, 130]}, {"key": "safety-and", "type": "definition", "offset": [149, 159]}, {"key": "primary-endpoints", "type": "clause", "offset": [219, 236]}, {"key": "applicable-regulatory-authorities", "type": "definition", "offset": [259, 292]}, {"key": "the-protocol", "type": "clause", "offset": [297, 309]}, {"key": "relating-to", "type": "definition", "offset": [310, 321]}], "samples": [{"hash": "4J8RrIIAjFs", "uri": "/contracts/4J8RrIIAjFs#phase-i-study", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 27.0177955627, "published": true}, {"hash": "3d81KByYAFb", "uri": "/contracts/3d81KByYAFb#phase-i-study", "label": "License Agreement (Clearside Biomedical, Inc.)", "score": 25.70362854, "published": true}, {"hash": "jsGPsB7eADY", "uri": "https://ir.clearsidebio.com/static-files/ddb11e8f-439a-43b2-845d-7bdd892178e1", "label": "ir.clearsidebio.com", "score": 9.9637231827, "published": false}], "snippet": "means a clinical study of the Covered Product in human volunteers or patients the purpose of which is preliminary determination of pharmacokinetics, safety and tolerability of a dosing regime and for which there are no primary endpoints (as understood by the applicable Regulatory Authorities) in the protocol relating to efficacy.", "hash": "797fee8f3008565fd2b7d239cfd6e22f", "id": 3}, {"size": 9, "snippet_links": [{"key": "phase-i-clinical-trial", "type": "definition", "offset": [8, 30]}, {"key": "as-prescribed", "type": "definition", "offset": [31, 44]}, {"key": "fda-regulations", "type": "definition", "offset": [59, 74]}], "samples": [{"hash": "1pgJyXuPhyy", "uri": "/contracts/1pgJyXuPhyy#phase-i-study", "label": "Co Development and Co Commercialization Agreement", "score": 31.3408622742, "published": true}, {"hash": "fvMI8zKYVhy", "uri": "/contracts/fvMI8zKYVhy#phase-i-study", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "lsJTxHgnCWq", "uri": "/contracts/lsJTxHgnCWq#phase-i-study", "label": "Collaboration Agreement (Xoma LTD /De/)", "score": 18.0, "published": true}], "snippet": "means a Phase I clinical trial as prescribed by applicable FDA regulations, or corresponding regulations of any comparable entity.", "hash": "006ff2d71d147f151d15308a1fbb5d41", "id": 4}, {"size": 8, "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "purpose-of", "type": "clause", "offset": [69, 79]}, {"key": "to-establish", "type": "clause", "offset": [89, 101]}, {"key": "determine-the", "type": "clause", "offset": [135, 148]}, {"key": "actions-of-the", "type": "clause", "offset": [214, 228]}, {"key": "side-effects", "type": "clause", "offset": [264, 276]}, {"key": "associated-with", "type": "definition", "offset": [277, 292]}, {"key": "evidence-of-effectiveness", "type": "clause", "offset": [342, 367]}, {"key": "foreign-equivalent", "type": "definition", "offset": [424, 442]}], "samples": [{"hash": "6mbmHp09FMZ", "uri": "/contracts/6mbmHp09FMZ#phase-i-study", "label": "Research and Development Collaboration Agreement (NextCure, Inc.)", "score": 30.2758388519, "published": true}, {"hash": "avpmikwIzWh", "uri": "/contracts/avpmikwIzWh#phase-i-study", "label": "Research and Development Collaboration Agreement (NextCure, Inc.)", "score": 30.0787124634, "published": true}], "snippet": "means a human clinical trial of a compound or product, the principal purpose of which is to establish an initial safety profile and to determine the metabolism, pharmacokinetics, pharmacodynamics and pharmacologic actions of the compound or product in humans, the side effects associated with increasing doses and, if possible, to gain early evidence of effectiveness, as more fully defined in 21 C.F.R. \u00a7 312.21(a), or its foreign equivalent.", "hash": "ee80c51122052584912952353dd839d5", "id": 5}, {"size": 7, "snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "purpose-of", "type": "clause", "offset": [61, 71]}, {"key": "determination-of", "type": "clause", "offset": [83, 99]}, {"key": "the-target", "type": "clause", "offset": [179, 189]}, {"key": "patient-population", "type": "definition", "offset": [190, 208]}, {"key": "relevant-regulatory-authority", "type": "definition", "offset": [227, 256]}, {"key": "from-time-to-time", "type": "clause", "offset": [258, 275]}, {"key": "applicable-law", "type": "definition", "offset": [289, 303]}, {"key": "as-amended", "type": "definition", "offset": [376, 386]}], "samples": [{"hash": "hWVAGZVVnqr", "uri": "/contracts/hWVAGZVVnqr#phase-i-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 33.0082130432, "published": true}, {"hash": "1CzYHXEctyp", "uri": "/contracts/1CzYHXEctyp#phase-i-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 32.8959617615, "published": true}, {"hash": "gb5lRg1Fw4l", "uri": "/contracts/gb5lRg1Fw4l#phase-i-study", "label": "Sublicense Agreement (Akouos, Inc.)", "score": 31.4257354736, "published": true}], "snippet": "means a study of a Licensed Product in humans, the principal purpose of which is a determination of safety, tolerability or pharmacokinetics in healthy individuals or patients in the target patient population prescribed by the relevant Regulatory Authority, from time to time, pursuant to applicable law or otherwise, including the trials referred to in 21 C.F.R. \u00a7312.21(a), as amended.", "hash": "f2f66e3d2a8eed8f8d0a5d39ff39a3cd", "id": 6}, {"size": 7, "snippet_links": [{"key": "clinical-study", "type": "definition", "offset": [16, 30]}, {"key": "a-limited", "type": "clause", "offset": [121, 130]}, {"key": "patient-population", "type": "definition", "offset": [131, 149]}, {"key": "the-product", "type": "definition", "offset": [224, 235]}], "samples": [{"hash": "f0gfXfivcnd", "uri": "/contracts/f0gfXfivcnd#phase-i-study", "label": "License and Collaboration Agreement", "score": 35.7160072327, "published": true}, {"hash": "iCqvmNU3r7W", "uri": "/contracts/iCqvmNU3r7W#phase-i-study", "label": "License and Collaboration Agreement (PTC Therapeutics, Inc.)", "score": 24.3702945709, "published": true}, {"hash": "ebRpQwcMAxY", "uri": "/contracts/ebRpQwcMAxY#phase-i-study", "label": "License and Collaboration Agreement (PTC Therapeutics, Inc.)", "score": 24.2087612152, "published": true}], "snippet": "means any human clinical study of a Product that is intended as initial clinical safety testing in healthy volunteers or a limited patient population, or studies directed toward understanding the mechanisms or metabolism of the Product.", "hash": "65b61890b8af459da011ab5d0e7c01a7", "id": 7}, {"size": 7, "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "the-requirements", "type": "clause", "offset": [63, 79]}, {"key": "as-amended", "type": "definition", "offset": [105, 115]}, {"key": "the-fda", "type": "clause", "offset": [174, 181]}, {"key": "phase-ii-study", "type": "definition", "offset": [203, 217]}, {"key": "phase-iii-study", "type": "definition", "offset": [221, 236]}], "samples": [{"hash": "fn89oPWGzh7", "uri": "/contracts/fn89oPWGzh7#phase-i-study", "label": "License Agreement (Lirum Therapeutics, Inc.)", "score": 35.0862426758, "published": true}, {"hash": "dn4d44bXHlQ", "uri": "/contracts/dn4d44bXHlQ#phase-i-study", "label": "License Agreement (Lirum Therapeutics, Inc.)", "score": 34.4647483826, "published": true}], "snippet": "means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. \u00a7312.21(a) (as amended) (whether or not such trial is intended for submission to the FDA), but which is not a Phase II Study or Phase III Study.", "hash": "95532d6b21cc3cd286567e0269d9fd67", "id": 8}, {"size": 4, "snippet_links": [{"key": "submission-and-approval-process", "type": "clause", "offset": [35, 66]}, {"key": "purpose-of", "type": "clause", "offset": [143, 153]}, {"key": "rules-and-regulations", "type": "clause", "offset": [281, 302]}, {"key": "future-revisions", "type": "clause", "offset": [354, 370]}, {"key": "clinical-trial", "type": "definition", "offset": [413, 427]}, {"key": "the-united-states", "type": "definition", "offset": [468, 485]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [487, 513]}, {"key": "a-phase", "type": "definition", "offset": [531, 538]}, {"key": "safety-and", "type": "definition", "offset": [557, 567]}, {"key": "phase-ii-study", "type": "definition", "offset": [634, 648]}], "samples": [{"hash": "G2IjZLlbjM", "uri": "/contracts/G2IjZLlbjM#phase-i-study", "label": "Patent and Technology License Agreement (Moleculin Biotech, Inc.)", "score": 34.2183418274, "published": true}, {"hash": "aZl8J6zn5HO", "uri": "/contracts/aZl8J6zn5HO#phase-i-study", "label": "Patent and Technology License Agreement (Moleculin Biotech, Inc.)", "score": 33.2245025635, "published": true}, {"hash": "8ykZRZQXgOt", "uri": "/contracts/8ykZRZQXgOt#phase-i-study", "label": "Patent and Technology License Agreement (Moleculin Biotech, Inc.)", "score": 33.2245025635, "published": true}], "snippet": "means: (a) that portion of the FDA submission and approval process which provides for the first introduction into humans of a product with the purpose of determining human toxicity, metabolism, absorption, elimination and other pharmacological action, as more fully defined by the rules and regulations of the FDA, including 21 C.F.R. \u00a7 312.21(a) or any future revisions or substitutes therefor; or (b) a similar clinical trial in any national jurisdiction other than the United States. For the avoidance of doubt, the emphasis of a PHASE I STUDY is on the safety and tolerability of a product and is used to plan patient dosing in a PHASE II STUDY.", "hash": "7df20c7da7504a5ec88a4d6525b83835", "id": 9}, {"size": 4, "snippet_links": [{"key": "section-52", "type": "clause", "offset": [14, 25]}], "samples": [{"hash": "cdz00RDsplq", "uri": "/contracts/cdz00RDsplq#phase-i-study", "label": "Contribution Agreement (Presidio Golf Trust)", "score": 18.0, "published": true}, {"hash": "buKe1xlHYGQ", "uri": "/contracts/buKe1xlHYGQ#phase-i-study", "label": "Contribution Agreement (Presidio Golf Trust)", "score": 18.0, "published": true}, {"hash": "75suriBLPzW", "uri": "/contracts/75suriBLPzW#phase-i-study", "label": "Contribution/Purchase and Sale Agreement (Presidio Golf Trust)", "score": 18.0, "published": true}], "snippet": "As defined in Section 5.2.", "hash": "67480fac9e382eca891c2462177e7100", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWcGhhc2UtaS1zdHVkeSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 283, "title": "Phase I Study", "snippet": "means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. \u00a7 312.21(a) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "id": "phase-i-study", "examples": ["Notwithstanding anything in Section 5 or elsewhere in the Agreement to the contrary, the Parties agree that during the Moderna Lead Period, Moderna will have primary responsibility for conducting communications with the TGA (and any other applicable Regulatory Authorities) that pertain to the RSV IND or relate to the performance of the RSV <strong>Phase I Study</strong> or otherwise relate to the Moderna RSV Lead Activities, including [***].", "Notwithstanding the terms of Section 3.6(b), all Manufacturing Costs necessary to produce Product in sufficient volumes and quality necessary for conduct of the first <strong>Phase I Study</strong> of the first Product in the Field will be borne [*] percent ([*]%) by Alexion and [*] percent ([*]%) by XOMA.", "Notwithstanding anything in Section 5 or elsewhere in the Agreement to the contrary, but subject to Sections 2.3 and 2.4 of this Third Amendment, the Parties acknowledge and agree that during the Moderna Lead Period, Moderna will have primary responsibility for preparing and maintaining all Regulatory Filings with respect to the RSV IND and RSV <strong>Phase I Study</strong>, and conducting the RSV <strong>Phase I Study</strong>, in each case in accordance with this Third Amendment and the Amended RSV R&amp;D Plan.", "The <strong>Phase I Study</strong>, the asbestos study and the Phase II Study are each sometimes hereinafter referred to as a &quot;Study.&quot; The cost of each Study shall be borne equally by Seller and Buyer.", "The costs of conducting and obtaining the <strong>Phase I Study</strong> and the Structural Report shall be the responsibility of Buyer.", "The costs of conducting and obtaining any such <strong>Phase I Study</strong> and the Structural Report or of otherwise performing any other Inspections shall be the responsibility of Buyer.", "If within [***] days after delivery of the Phase 1 Study Materials Licensee does not exercise the Collaboration Candidate Option with respect to such Collaboration Candidate, Licensor shall have the right to proceed with such Phase 1 Study in accordance with the <strong>Phase I Study</strong> Material, at its own cost.", "Upon Angiotech\u2019s reasonable request and to the extent permitted by applicable law, within thirty (30) days after the completion of each such <strong>Phase I Study</strong> hereunder, Athersys shall assign and transfer to Angiotech Athersys\u2019 entire right, title and interest in and to any corresponding IND and other regulatory filings and documentation pertaining thereto.", "Angiotech shall have the primary responsibility for communicating with any regulatory authority regarding any IND application or other regulatory filing pertaining to a Clinical Development Candidate that has completed a <strong>Phase I Study</strong>, and regarding any Clinical Development Candidate or Cell Therapy Product that has been submitted for, or has obtained, Regulatory Approval.", "Athersys shall have the primary responsibility for communicating with any regulatory authority regarding any IND application or other regulatory filing pertaining to a Clinical Development Candidate that has not yet completed a <strong>Phase I Study</strong>."], "related": [["phase-ii-study", "Phase II Study", "Phase II Study"], ["phase-iii-study", "Phase III Study", "Phase III Study"], ["phase-i-clinical-study", "Phase I Clinical Study", "Phase I Clinical Study"], ["phase-i-trial", "Phase I Trial", "Phase I Trial"], ["phase-ii-clinical-study", "Phase II Clinical Study", "Phase II Clinical Study"]], "related_snippets": [], "updated": "2026-03-14T06:33:37+00:00"}, "json": true, "cursor": ""}}